{
    "clinical_study": {
        "@rank": "23623", 
        "arm_group": {
            "arm_group_label": "Gemcitabine Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating elderly women\n      who have metastatic breast cancer."
        }, 
        "brief_title": "Management of Metastatic Breast Cancer in Frail Patients", 
        "completion_date": {
            "#text": "June 2000", 
            "@type": "Actual"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the safety and efficacy of gemcitabine in the treatment of elderly\n      women with metastatic breast cancer. II. Evaluate the quality of life in these patients.\n\n      OUTLINE: Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8\n      week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in\n      the absence of disease progression or unacceptable toxicity. Quality of life is assessed\n      prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2\n      years, then every 6 months until year 5, and then annually thereafter.\n\n      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study over 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Metastatic breast cancer Measurable disease No progression after\n        3 or more different forms of chemotherapy Hormone receptor positive breast cancer must be\n        refractory to at least two forms of hormonal treatment (including antiestrogen, aromatase\n        inhibitor, and/or progestin) unless there is life threatening metastases (e.g.,\n        lymphangitic metastases to the lung or liver metastases) Must meet at least one of the\n        following characteristics for frailty: ECOG 2-4 Dependence in at least one activity of\n        daily living 85 and over History of three or more falls in the past 6 months Mild dementia\n        (must be oriented in time, space, and location) Three or more comorbid conditions Hormone\n        receptor status: Not specified\n\n        PATIENT CHARACTERISTICS: Age: 65 and over Sex: Female Menopausal status: Not specified\n        Performance status: See Disease Characteristics Life expectancy: Greater than 12 weeks\n        Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least\n        100,000/mm3 Neutropenia or thrombocytopenia secondary to myelophthisis from breast cancer\n        allowed Hepatic: Increased bilirubin allowed Renal: Renal insufficiency allowed\n        Cardiovascular: Congestive heart failure allowed Other: No known allergy to gemcitabine\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease\n        Characteristics Endocrine therapy: See Disease Characteristics Radiotherapy: At least 4\n        weeks since prior radiotherapy to bony areas or CNS metastases Surgery: Not specified\n        Other: Concurrent bisphosphonates allowed No concurrent participation in other\n        investigational studies"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005614", 
            "org_study_id": "MCC-11909", 
            "secondary_id": "NCI-G00-1748"
        }, 
        "intervention": {
            "arm_group_label": "Gemcitabine Treatment", 
            "description": "Gemcitabine via IV", 
            "intervention_name": "Gemcitabine hydrochloride", 
            "intervention_type": "Drug", 
            "other_name": "Gemzar"
        }, 
        "intervention_browse": {
            "mesh_term": "Gemcitabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage IV breast cancer", 
            "recurrent breast cancer"
        ], 
        "lastchanged_date": "September 21, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MCC-11909"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Management of Metastatic Breast Cancer in Frail Patients", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Lodovico Balducci, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2000", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Investigators planned to determine efficacy (objective response rate [ORR] by Response Evaluation Criteria In Solid Tumors [RECIST]).", 
            "measure": "Objective Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005614"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Investigators planned to review adverse events utilizing Common Toxicity Criteria (CTC) V3.", 
            "measure": "Number of Participants with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 1999", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012", 
        "why_stopped": "no accrual"
    }, 
    "geocoordinates": {}
}